Feasibility study of TC(docetaxel+Cyclophosphamide)as adjuvant chemotherapy for intermediate risk primary breast cancer with HER2-negative and ER-positive tumor(KBC-SG 0803) - Feasibility study of TC (docetaxel+cyclophosphamide) as adjuvant chemotherapy for intermediate risk primary breast cancer with HER2-negative and ER-positive tumor (KBC-SG 0803)

Kyushu Breast Cancer Study Group0 个研究点目标入组 102 人开始时间: 2008年12月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.History of bilateral breast cancer 2.History of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix 3.Inflammatory breast cancer 4.Male 5.A history of hypersensitivity reaction to any drugs. 6.Uncontrolled medical conditions. 7.Suspected of infection with fever 8.Severe peripheral neuropathy (>grade 1) 9.Symptomatic varicella. 10.HBs antigen positive 11.Treatment required pleural or pericardial effusions 12.Severe peripheral edema (>grade 1) 13.Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X-ray 14.Patients who are required concurrent treatment by corticosteroids except for premedication 15.Severe psychiatric disorders 16.Pregnant or lactation women, or women with suspected pregnancy 17.Patients judged by the investigator to be unfit to be enrolled into the study

发起方

Kyushu Breast Cancer Study Group